Amylyx Cuts Low Blood Sugar Episodes 55% After Bariatric Surgery

Amylyx Pharmaceuticals reported on August 18, 2026, that its investigational drug avexitide reduced dangerously low blood sugar episodes by 55% compared with placebo over 16 weeks in a 78-patient late-stage trial of people who developed post-bariatric hypoglycemia (PBH) after weight-loss surgery. The trial met its primary endpoint. The news sent Amylyx shares up more than 45% to $31.72 in morning trading, with the company on track to add roughly $1.15 billion to its market value. The significance is magnified by the fact that no approved treatments exist for PBH, a condition that can develop after Roux-en-Y gastric bypass, one of the most commonly performed bariatric procedures. Post-bariatric hypoglycemia is more than an inconvenience. It can cause cognitive impairment, loss of consciousness, or seizures, and currently patients rely on dietary changes, blood sugar monitoring, and carbohydrate-blocking medications. Dr. Marilyn Tan, the study's lead investigator, said patients "want more than anything to reduce the number of hypoglycemia events so that they can live independently without the fear." That patient-centric framing matters because frequency of events is a hard clinical endpoint that directly affects quality of life. Stifel analyst James Condulis called the 55% reduction a "best-case scenario" and better than investors expected, reflecting the market's prior skepticism after Amylyx's earlier pipeline failure. Avexitide's mechanism distinguishes it from most diabetes and obesity drugs. It blocks certain GLP-1 receptors in the pancreas, reducing excess insulin secretion and stabilizing blood glucose levels. In an era dominated by GLP-1 receptor agonists for diabetes and weight loss, avexitide works in the opposite direction on the same receptor family, potentially offering a targeted intervention for a patient population whose exaggerated insulin response drives hypoglycemia. The company said the once-daily injection was well tolerated, with mild-to-moderate side effects including diarrhea and bruising, suggesting a manageable safety profile in the trial population. For Amylyx, this readout marks a crucial turnaround. In 2024, the company was forced to pull its flagship ALS drug Relyvrio from the market after a late-stage trial failure, triggering layoffs and a corporate restructuring. Avexitide was acquired from Eiger BioPharmaceuticals for just $35.1 million, an asset now positioned as a potential blockbuster. With $250 million in cash, Amylyx said it is moving "expeditiously" toward a U.S. marketing application by the end of 2026 and aims for a 2027 commercial launch. TD Cowen analysts project peak U.S. sales of $2.2 billion for avexitide, a figure that would transform Amylyx's revenue base. Investors are treating the results as a de-risking event. The single-day share move added more than $1 billion in market capitalization, reflecting confidence that avexitide can become the first approved therapy for PBH. The low acquisition price, the clear primary endpoint win, and the absence of competing approved therapies create a favorable commercial backdrop. Analysts' peak sales estimate of $2.2 billion is substantial for a company that had to rebuild after Relyvrio, and it suggests the market sees PBH as an underserved category with meaningful prevalence among bariatric surgery patients. Still, important questions remain. The trial enrolled only 78 patients and followed them for 16 weeks, so the durability of benefit, long-term safety, and performance in broader patient subgroups will be critical as the company prepares its regulatory submission. The FDA filing is expected by the end of 2026, and approval would establish a new therapeutic category. Commercial uptake will also depend on how easily physicians identify PBH, how the drug is integrated into post-surgical care pathways, and whether payers recognize the value of avoiding severe hypoglycemia-related injury or hospitalization. Looking ahead, Amylyx's ability to execute a clean regulatory filing and launch will be the next test. If avexitide reaches the market in 2027 as planned, it could provide the first evidence of a viable pharmaceutical treatment for a condition that has lacked options. The company's turnaround from Relyvrio's failure to a potential first-in-class drug demonstrates how a small, well-timed acquisition and a focused clinical program can reshape a biotech's trajectory. The coming months will reveal whether the promising data translate into approval and commercial traction, but for now the readout has restored investor confidence and given patients and clinicians a reason to watch the space closely.